Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6420MR)

This product GTTS-WQ6420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6420MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6879MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ434MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ7109MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ8363MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3765MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ7431MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ5259MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW